FDA Proposes New Vaccine Oversight Following Controversial Memo

The Food and Drug Administration (FDA) is advocating for enhanced oversight of vaccine trials and approvals following an internal memo that links the deaths of at least ten children to COVID-19 vaccines. The memo, obtained by The New York Times, has not been publicly released and lacks specific details, including the ages of the children and any underlying health conditions they may have had.

Dr. Vinay Prasad, the director of the FDA’s vaccine division, authored the memo and circulated it to agency staff on March 22, 2025. He indicated that the FDA would acknowledge for the first time that COVID-19 vaccines may have resulted in fatalities among American children. The memo suggested a connection between these deaths and myocarditis, an inflammation of the heart muscle often observed in young males after vaccination.

Robert F. Kennedy Jr., the Health Secretary, has been vocal in questioning the safety of vaccines, a stance that has drawn criticism from public health experts. His leadership has been marked by an inclination to scrutinize vaccinations more rigorously. As part of this approach, his administration proposed new policies that limit access to COVID-19 vaccines for individuals under 65, except for those with pre-existing health conditions.

The implications of this memo are significant. It arrives just before a meeting of the Centers for Disease Control and Prevention’s (CDC) influential vaccine committee, which is set to discuss the children’s immunization schedule and the hepatitis B vaccine for newborns. Critics, including Michael Osterholm, an infectious disease expert at the University of Minnesota, argue that releasing the memo ahead of the meeting demonstrates a lack of responsibility when addressing public health matters.

Prasad’s memo outlines several proposed changes to vaccine oversight. These include requiring comprehensive studies that encompass all demographic subgroups, such as pregnant women, and reevaluating the annual process for updating flu vaccines, which he described as “a catastrophe of low-quality evidence.” The memo also emphasizes the necessity for vaccine manufacturers to conduct larger studies to verify the safety of administering multiple vaccines concurrently, such as the flu and COVID-19 shots.

The proposed changes could significantly increase the costs for vaccine manufacturers, which would need to submit more extensive studies to the FDA for approval. Public health experts express concern that high-profile declarations questioning vaccine safety could undermine public confidence, especially as cases of measles and whooping cough are on the rise in the United States.

Dr. Paul Offit, a vaccine expert at the Children’s Hospital of Philadelphia, criticized the memo as an instance of “science by press release,” highlighting the lack of context regarding deaths from COVID-19 among vaccinated and unvaccinated children. He underscored the importance of presenting a balanced view of vaccine risks and benefits, particularly given that approximately 2,100 children have died from COVID-19 since the pandemic began, according to the American Academy of Pediatrics.

The FDA’s renewed focus on vaccine oversight under Prasad’s leadership reflects ongoing tensions within the agency. In a recent communication, he urged staff members to avoid publishing studies that do not align with the FDA’s mission, indicating a desire to consolidate authority over vaccine-related research and policy.

As this situation unfolds, the implications for vaccine policy and public health remain significant. The proposed regulatory measures could reshape the landscape of vaccination in the United States, potentially impacting access and safety protocols for various vaccines.